Researchers are edging closer to something long imagined but never quite within reach: a single vaccine platform that could ...

Cancer has long been medicine’s most elusive target, but a wave of new research suggests scientists may finally be closing in ...

A groundbreaking lung cancer vaccine will be tested on humans from summer 2026, with British scientists working on jabs for ...

At the Cleveland Clinic, researchers are testing a preventive breast cancer vaccine, and results from Phase 1 of the trial are showing promising signs.

An analysis of ongoing trials suggests that mRNA cancer vaccines have the potential to deliver health benefits worth $75 ...

The trial targeting triple-negative breast cancer, which disproportionately affects Black women, induced immune responses in nearly three-quarters of participants.

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine.

With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full ...

A preliminary study found that people receiving immunotherapy for lung cancer or melanoma lived longer if they had received ...

Last August, Labroots covered the decision of the National Health Service of England (NHS England) to allow subcutaneous (under the skin) injections of programmed death ligand 1 (PD-L1) blocker called ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

In a statement accompanying the announcement of Risch to the cancer panel, HHS Secretary Robert F. Kennedy Jr. — himself a ...